icaria-MM: sarclisa + POMALIDOMIDE AND DEXAMETHASONE (Pd)
icaria-MM Patient
Profiles
Treating with sarclisa + Pd as early as
first relapse1
Current patient information
68 years of age
High: t(4;14)
ECG shows EF 45%,
uncontrolled hypertension
Diagnosis
Diagnosed 3 years ago after work-up for fatigue revealed anemia
1st line
VRd induction → ASCT → bortezomib and lenalidomide maintenance (CR for 30 months posttransplant)
1st relapse
Peripheral neuropathy; relapsed with new lesion in humerus found on MRI
2nd-line treatment considerations for Laura
- High cytogenetic risk
- Cardiovascular comorbidities
- Double refractory to lenalidomide and bortezomib
- Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®
consider sarclisa + Pd as early as first relapsefor patients with high cytogenetic risk and patients with cardiovascular
comorbidities1
PFS in the intent-to-treat population1
- mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
ASCT=autologous stem cell transplant; CR=complete response; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group performance status; EF=ejection fraction; IMiD=immunomodulatory drug; mAb=monoclonal antibody; mPFS=median progression-free survival; MRI=magnetic resonance imaging; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.
PFS results in patients with high cytogenetic risk
and patients refractory to lenalidomide
In icaria-MM, 20% of patients had high cytogenetic risk* and 93%
were refractory to lenalidomide1
PFS in patients with high cytogenetic risk2,3
Reduction in the risk of
disease progression
HR=0.66 (95% CI: 0.33, 1.28)
PFS in patients refractory to lenalidomide4
Reduction in the risk of
disease progression
HR=0.59 (95% CI: 0.43, 0.82)
See the full icaria-mm patient subgroup data
Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.
*Cytogenetics by central lab; cutoff 50% for del(17p), 30% for t(4;14) and t(14;16).3
Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1
See ICARIA-MM Trial Design
Current patient information
78 years of age
Standard
(eGFR)
48 mL/min/1.73 m2
Diagnosis
Diagnosed ~3.5 years ago after presenting with anemia, moderate renal insufficiency, mild hypercalcemia, and severe osteoporosis; transplant ineligible
1st line
VRd induction → lenalidomide maintenance (VGPR for 36 months); developed persistent peripheral neuropathy during induction
1st relapse
Relapse confirmed after consecutive labs showed increase of M-protein and light chains, recurrence of hypercalcemia, and reappearance of renal insufficiency
2nd-line treatment considerations for Ben
- Elderly
- Impaired renal function
- Refractory to lenalidomide
- Developed neuropathy from prior bortezomib treatment
- Candidate for a triplet combination that includes a multimodal anti-CD38 mAb and a third-generation IMiD®
consider sarclisa + Pd as early as first relapsefor elderly patients and patients with impaired renal function1
PFS in the intent-to-treat population1
- mPFS: 11.53 months with SARCLISA + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010)
This is a hypothetical case study portrayed by an actor and should not substitute a healthcare provider's decision.
ECOG PS=Eastern Cooperative Oncology Group performance status; eGFR=estimated glomerular filtration rate; IMiD=immunomodulatory drug; mAb=monoclonal antibody; M-protein=monoclonal protein; mPFS=median progression-free survival; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma; VGPR=very good partial response; VRd=bortezomib, lenalidomide, dexamethasone.
PFS results in elderly patients and
patients with impaired renal function
In icaria-MM, 20% of patients were elderly (≥75 years) and
36% had impaired renal function3*
PFS in elderly patients (≥75 years)2,3
Reduction in the risk of
disease progression
HR=0.48 (95% CI: 0.24, 0.95)
PFS in patients with renal impairment2,3
Reduction in the risk of
disease progression
HR=0.50 (95% CI: 0.30, 0.85)
See the full icaria-mm patient subgroup data
Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.
*eGFR <60 mL/min/1.73 m2.1
Review the broad and diverse patient population studied in the phase 3 ICARIA-MM trial1
See ICARIA-MM Trial Design